AnthroPod is produced by the Society for Cultural Anthropology. In each episode, we explore what anthropology teaches us about the world and people around us.
…
continue reading
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems
MP3•Episode home
Manage episode 493440358 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems CME Available: https://auau.auanet.org/node/43047 At the conclusion of this activity, participants will be able to: 1. Implement current practice guidelines and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills. 2. Identify the best intravesical agent and duration of therapy for low-, intermediate-, and high-risk NMIBC and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. 5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs. ACKNOWLEDGEMENTS: This educational activity is supported by an independent educational grants from: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
…
continue reading
394 episodes
MP3•Episode home
Manage episode 493440358 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems CME Available: https://auau.auanet.org/node/43047 At the conclusion of this activity, participants will be able to: 1. Implement current practice guidelines and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills. 2. Identify the best intravesical agent and duration of therapy for low-, intermediate-, and high-risk NMIBC and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. 5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs. ACKNOWLEDGEMENTS: This educational activity is supported by an independent educational grants from: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
…
continue reading
394 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.